For research use only. Not for therapeutic Use.
Zansecimab (LY-3127804) is an immunoglobulin G4-kappa, a monoclonal antibody against angiopoietin 2 (Ang 2). Zansecimab has potential applications in angiogenesis and immune regulation[1][2][3].
| Catalog Number | I041614 |
| CAS Number | 2415205-37-5 |
| Purity | ≥95% |
| Reference | [1]. Yen CC, et al. Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opin Drug Saf. 2022 Feb;21(2):157-166. [2]. Wang Y, et al. Angiogenesis as a potential treatment strategy for rheumatoid arthritis. Eur J Pharmacol. 2021 Nov 5;910:174500. |
